Insulin degludec

What is Insulin Degludec?

Insulin degludec is an innovative, ultra-long-acting insulin analogue designed to provide consistent and prolonged blood glucose control for individuals living with diabetes. Marketed globally under the brand name Tresiba, this advanced insulin is a cornerstone in modern diabetes management. Unlike conventional long-acting insulins, insulin degludec forms soluble multi-hexamers upon subcutaneous injection, which leads to a slow and continuous release of insulin monomers into the bloodstream. This unique mechanism allows for a duration of action exceeding 42 hours, offering unparalleled flexibility in dosing schedules and a reduced risk of hypoglycemia, particularly nocturnal episodes.

As a basal insulin, its primary role is to mimic the body's natural background insulin secretion, maintaining stable blood glucose levels between meals and overnight. It is a crucial component of therapy for both type 1 diabetes and type 2 diabetes, helping patients achieve better glycemic control and improve their overall quality of life. Its consistent action profile makes it a valuable tool for healthcare providers aiming to optimize treatment regimens and minimize fluctuations in blood sugar.

How Does it Work?

The unique pharmacological profile of Insulin degludec stems from its molecular structure. When injected subcutaneously, it self-associates to form soluble multi-hexamers. These large complexes create a subcutaneous depot from which zinc slowly dissociates, allowing individual insulin degludec monomers to be gradually released into the circulation. This slow and sustained release mechanism ensures a stable and predictable insulin concentration over an extended period.

Once in the bloodstream, insulin degludec binds to insulin receptors on cells throughout the body, facilitating the uptake of glucose from the blood into muscles, fat, and other tissues. It also inhibits glucose production by the liver. The result is a steady reduction in blood glucose levels, mimicking the physiological release of basal insulin. This continuous and stable action helps prevent hyperglycemia throughout the day and night, contributing significantly to improved glycemic control without the pronounced peaks associated with some other insulins, thereby reducing the risk of hypoglycemic events.

Medical Uses

Insulin degludec is approved for the treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and older. It is indicated for:

• Type 1 diabetes: As part of a basal-bolus regimen, where it provides the foundational long-acting insulin, complemented by mealtime (bolus) insulin.
• Type 2 diabetes: It can be used alone, in combination with oral antidiabetic medications, or with other injectable antidiabetic drugs, including mealtime insulin. Its role is to help patients achieve and maintain target blood glucose levels.

The primary therapeutic goal of using insulin degludec is to improve long-term glycemic control, as measured by HbA1c levels, while minimizing the risk of hypoglycemia. Its ultra-long duration of action and low variability make it particularly beneficial for patients who require a flexible dosing schedule or those who experience frequent nocturnal hypoglycemia with other basal insulins.

Dosage

The dosage of Insulin degludec must be individualized based on the patient's metabolic needs, blood glucose monitoring results, and treatment goals. It is administered once daily, subcutaneously, at any time of day, but preferably at the same time each day. The flexibility allows for administration within an 8-hour window around the usual time of administration when necessary.

Initial Dosing Guidelines:

• For Type 1 Diabetes: The typical starting dose is approximately one-third to one-half of the total daily insulin requirement. The remaining daily insulin requirement is met by short- or rapid-acting insulin given with meals.
• For Type 2 Diabetes: A common starting dose is 10 units once daily, which is then adjusted based on the patient's fasting plasma glucose levels and individual response.

Dosage adjustments should always be made under the guidance of a healthcare professional, based on regular blood glucose monitoring. The insulin degludec FlexTouch prefilled pen is a common delivery device, making administration convenient for patients.

Side Effects

Like all medications, Insulin degludec can cause side effects, although not everyone experiences them. The most common side effect associated with insulin therapy, including insulin degludec, is hypoglycemia (low blood sugar).

Common Side Effects:

• Hypoglycemia: Symptoms include dizziness, sweating, confusion, headache, blurred vision, and irritability. It's crucial for patients to recognize and treat hypoglycemia promptly.
• Injection site reactions: Pain, redness, bruising, swelling, itching, or hardening at the injection site. These are usually mild and transient.
• Weight gain: Some patients may experience a modest increase in weight.

Less Common or Rare Side Effects:

• Lipodystrophy: Changes in fat tissue at the injection site (e.g., thickening or pitting of the skin). Rotating injection sites can help prevent this.
• Allergic reactions: Rare, but severe systemic allergic reactions (anaphylaxis) can occur, requiring immediate medical attention. Symptoms may include rash, itching, sweating, stomach upset, and difficulty breathing.
• Peripheral edema: Swelling in the hands or feet.

Patients should always discuss potential side effects with their doctor and report any concerning symptoms.

Drug Interactions

Several medications can affect blood glucose levels and may require adjustment of the Insulin degludec dose. It is crucial for patients to inform their healthcare provider about all medications they are taking, including over-the-counter drugs, supplements, and herbal remedies.

Drugs that may intensify the blood-glucose-lowering effect:

• Oral antidiabetic agents, GLP-1 receptor agonists, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, octreotide, somatostatin analogues, propoxyphene, salicylates, sulfonamide antibiotics.
• Beta-blockers can mask symptoms of hypoglycemia, making it harder for patients to recognize when their blood sugar is too low.
• Alcohol can either potentiate or reduce the hypoglycemic effect of insulin.

Drugs that may reduce the blood-glucose-lowering effect:

• Corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, somatropin, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), atypical antipsychotic medicinal products (e.g., olanzapine and clozapine), protease inhibitors.

Regular blood glucose monitoring is essential when starting or stopping any medication to ensure proper dose adjustment of insulin degludec and maintain optimal glycemic control.

FAQ

Q: What is the main difference between Insulin Degludec and other long-acting insulins?

A: The primary difference lies in its ultra-long duration of action, exceeding 42 hours. This provides greater flexibility in dosing time (allowing an 8-hour window) and has been associated with a lower risk of nocturnal hypoglycemia compared to some other long-acting insulins.

Q: Can Insulin Degludec be mixed with other insulins?

A: No, Insulin degludec should not be mixed with other insulins in the same injection. If you need to take both a basal and a mealtime insulin, they should be administered as separate injections.

Q: How quickly does Insulin Degludec start to work?

A: Insulin degludec begins to lower blood sugar within 30-90 minutes after injection. However, its full effect is gradual and sustained, providing a steady glucose-lowering action over more than 42 hours, rather than a rapid peak.

Q: Is Insulin Degludec safe for children?

A: Yes, insulin degludec is approved for use in children aged 1 year and older with type 1 diabetes or type 2 diabetes. Dosage must be carefully determined and monitored by a healthcare professional.

Q: What should I do if I miss a dose?

A: If a dose is missed, take the next dose as soon as you remember, then continue with your once-daily schedule. Ensure there are at least 8 hours between consecutive doses. Never take a double dose to make up for a missed one.

Products containing Insulin degludec are available through trusted online pharmacies. You can browse Insulin degludec-based medications at ShipperVIP or Medicenter.

Summary

Insulin degludec represents a significant advancement in the treatment of diabetes, offering an ultra-long-acting insulin option with a unique profile. Its extended duration of action and low variability provide consistent glycemic control, reduce the risk of hypoglycemia (especially at night), and offer patients greater flexibility in their daily dosing schedule. As a foundational basal insulin, it plays a critical role in the comprehensive diabetes management plans for individuals with both type 1 diabetes and type 2 diabetes. While generally well-tolerated, awareness of potential side effects and drug interactions is crucial. Patients should always consult with their healthcare provider to determine if insulin degludec is the appropriate treatment for their individual needs and to ensure proper dosing and monitoring.